 | This articleis anorphan, as no other articleslink to it. Pleaseintroduce links to this page fromrelated articles.(April 2022) |
TheEuropean Bank for induced pluripotent Stem Cells (EBiSC) is a non-profitinduced pluripotent stem cell (iPSC)biorepository and service provider with central facilities in Germany and the United Kingdom.
EBiSC was set up between 2014 and 2017 by a consortium that represented researchers, clinicians and industry stakeholders.[1] A second phase of the project runs between 2019 and 2022 with the aim of consolidating EBiSC as a not-for-profit, self-sustainable iPSC bank and service provider.[2] The initiative was funded by theEuropean Commission and theEuropean Federation of Pharmaceutical Industries and Associations under theInnovative Medicines Initiative.[3][4]
The European Bank for induced pluripotent Stem Cells performs collection, banking, quality control and distribution of iPSC lines for research purposes. EBiSC's stated goal is to supply academic, non-profit and commercial researchers with quality-controlled, disease-relevant iPSC lines, data and other services. It also seeks to promote the internationalstandardisation of iPSC banking practices and to act as a central hub that ensures the sustainability and accessibility of iPSC lines generated by different research organisations. IPSC lines generated externally can be deposited into EBiSC for storage, banking, quality control and distribution.[5][6][7][8]
In February 2020, the EBiSC catalogue contained iPSC lines representing diseases and conditions such asAlzheimer's disease,[9]Frontotemporal Dementia,Parkinson's disease,Huntington's disease,Dravet syndrome,Bardet-Biedl syndrome,depression andpain,diabetes mellitus,eye diseases andheart disease.[10] These iPSC lines have been deposited into EBiSC by academic institutions and non-profit and commercial organisations internationally. This includes lines generated within research projects such as StemBANCC, HipSci, IMI-ADAPTED, CRACK IT BadIPS and CRACK IT UnTangle.
The EBiSC Bank is run collaboratively by Fraunhofer UK Research Ltd in Glasgow, Scotland and theFraunhofer Institute for Biomedical Engineering (IBMT) in Germany.